Bristol-Myers Squibb Co. announced today (March 25) that it has received FDA approval for ipilimumab, the first drug in a new family of medicines to treat advanced melanoma, the most deadly form of skin cancer.
This is potentially good news for those of us who are fighting advanced prostate cancer as there is currently an active trial using ipilimumab. This approval will mean that one of the two hurdles for FDA approval has been met, the drug is considered safe. The next step is to see if the men in the clinical trial experience any survival advantage.
On the Horizon – Ipilimumab
Joel T. Nowak, M.A., M.S.W.